{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:05:39Z","timestamp":1790723139263,"version":"4.1.0"},"posted":{"date-parts":[[2026,9,29]]},"group-title":"In Review","reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,15]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\n Fragile X syndrome (FXS) is caused by a CGG repeat expansion in the\n                  <italic>FMR1<\/italic>\n                  gene on chromosome X that leads to hypermethylation and reduces or completely silences the expression of\n                  <italic>FMR1<\/italic>\n                  mRNA and its protein product, Fragile X Messenger Ribonucleoprotein (FMRP). Since the clinical manifestations of FXS can be variable, there is interest in identifying molecular markers that reflect phenotypic severity. The extent of CGG repeat expansion and resulting hypermethylation varies substantially between patients, suggesting that\n                  <italic>FMR1<\/italic>\n                  gene silencing differs between individuals with FXS and could contribute to the phenotypic variability. Previous studies have identified\n                  <italic>FMR1<\/italic>\n                  mRNA as a highly reproducible, sensitive and quantitative measure of gene activity. This study builds on these previous studies and assesses the relationship between\n                  <italic>FMR1<\/italic>\n                  mRNA and clinical outcomes in FXS.\nMethods\n We recruited 300 study participants, including males and females across the following diagnostic groups: FXS, fragile X premutation carriers (PMCs), typically developing controls (TDC), and (non-FXS) developmental disability controls (DD). Peripheral blood samples were used for quantifying both\n                  <italic>FMR1<\/italic>\n                  mRNA and FMRP (from a Luminex-based assay). IQ and adaptive behavior were evaluated with the Stanford-Binet 5 and Vineland-3 tests, respectively. Analyses examined group- and sex-level associations between\n                  <italic>FMR1<\/italic>\n                  mRNA and FMRP, IQ, adaptive behavior, and age across diagnostic groups.\nResults\n                  <italic>FMR1<\/italic>\n                  mRNA was substantially reduced in participants with FXS, particularly males, consistent with expected gene silencing. Within the FXS group, higher\n                  <italic>FMR1<\/italic>\n                  mRNA levels were associated with higher IQ and better adaptive behavior. These associations were not observed in the TDC or DD comparison groups, suggesting that the relationship is specific to FXS pathology rather than developmental impairment more broadly.\n                  <italic>FMR1<\/italic>\n                  mRNA also correlated positively with FMRP in FXS, supporting its validity as a molecular marker. Age-related increases in\n                  <italic>FMR1<\/italic>\n                  mRNA were also observed in females with FXS.\nConclusions\n Our findings that\n                  <italic>FMR1<\/italic>\n                  mRNA correlates with both FMRP levels and clinical outcomes in participants with FXS support its utility as a clinically meaningful molecular marker of phenotypic severity. As an accessible surrogate of disease severity,\n                  <italic>FMR1<\/italic>\n                  mRNA may help improve prognostic assessment and support more individualized treatment planning in FXS.\n                <\/p>","DOI":"10.21203\/rs.3.rs-11053577\/v1","type":"posted-content","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:20:31Z","timestamp":1790720431000},"source":"Crossref","is-referenced-by-count":0,"title":["Association between FMR1 mRNA levels and clinical phenotypes in Fragile X syndrome"],"prefix":"10.21203","author":[{"given":"Braeden S.","family":"Heald","sequence":"first","affiliation":[{"name":"Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker S","family":"McKinney","sequence":"additional","affiliation":[{"name":"Children's Mercy Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Phelan-McDermid Syndrome Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli C.","family":"Dominick","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Lacher","sequence":"additional","affiliation":[{"name":"University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Piloto","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gross","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Erickson","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","article-title":"FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism","volume":"146","author":"Darnell JC","year":"2011","unstructured":"Darnell JC, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146(2):247\u201361.","journal-title":"Cell"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev.genom.8.080706.092249","article-title":"The pathophysiology of fragile x syndrome","volume":"8","author":"Penagarikano O","year":"2007","unstructured":"Penagarikano O, Mulle JG, Warren ST. The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet. 2007;8:109\u201329.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/jmg.32.12.925","article-title":"X inactivation of the FMR1 fragile X mental retardation gene","volume":"32","author":"Kirchgessner CU","year":"1995","unstructured":"Kirchgessner CU, Warren ST, Willard HF. X inactivation of the FMR1 fragile X mental retardation gene. J Med Genet. 1995;32(12):925\u20139.","journal-title":"J Med Genet"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1038\/s41598-022-09633-8","article-title":"Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots","volume":"12","author":"Boggs AE","year":"2022","unstructured":"Boggs AE, et al. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Sci Rep. 2022;12(1):5617.","journal-title":"Sci Rep"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1038\/s41598-023-29786-4","article-title":"A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome","volume":"13","author":"Straub D","year":"2023","unstructured":"Straub D, et al. A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome. Sci Rep. 2023;13(1):3808.","journal-title":"Sci Rep"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10100694","article-title":"A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments","volume":"10","author":"Budimirovic DB","year":"2020","unstructured":"Budimirovic DB et al. A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments. Brain Sci, 2020. 10(10).","journal-title":"Brain Sci"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1038\/s41598-017-02217-x","article-title":"Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data","volume":"7","author":"Taylor SC","year":"2017","unstructured":"Taylor SC, Laperriere G, Germain H. Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data. Sci Rep. 2017;7(1):2409.","journal-title":"Sci Rep"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1261\/rna.280807","article-title":"Elevated FMR1 mRNA in premutation carriers is due to increased transcription","volume":"13","author":"Tassone F","year":"2007","unstructured":"Tassone F, et al. Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA. 2007;13(4):555\u201362.","journal-title":"RNA"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1086\/302720","article-title":"Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome","volume":"66","author":"Tassone F","year":"2000","unstructured":"Tassone F, et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet. 2000;66(1):6\u201315.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"23058","DOI":"10.1038\/s41598-024-73626-y","article-title":"A near normal distribution of IQ in Fragile X syndrome","volume":"14","author":"Schmitt LM","year":"2024","unstructured":"Schmitt LM, et al. A near normal distribution of IQ in Fragile X syndrome. Sci Rep. 2024;14(1):23058.","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1636987","DOI":"10.3389\/fpsyt.2025.1636987","article-title":"Beyond the Fragile X protein: neighborhood characteristics explain individual differences in IQ and adaptive behaviors of Fragile X syndrome","volume":"16","author":"McKinney WS","year":"2025","unstructured":"McKinney WS, et al. Beyond the Fragile X protein: neighborhood characteristics explain individual differences in IQ and adaptive behaviors of Fragile X syndrome. Front Psychiatry. 2025;16:1636987.","journal-title":"Front Psychiatry"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"11701","DOI":"10.1038\/s41598-020-68465-6","article-title":"FMR1 mRNA from full mutation alleles is associated with ABC-C(FX) scores in males with fragile X syndrome","volume":"10","author":"Baker EK","year":"2020","unstructured":"Baker EK, et al. FMR1 mRNA from full mutation alleles is associated with ABC-C(FX) scores in males with fragile X syndrome. Sci Rep. 2020;10(1):11701.","journal-title":"Sci Rep"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"e0226811","DOI":"10.1371\/journal.pone.0226811","article-title":"Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions","volume":"14","author":"Kim K","year":"2019","unstructured":"Kim K, et al. Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS ONE. 2019;14(12):e0226811.","journal-title":"PLoS ONE"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1866-1955-6-16","article-title":"Improving IQ measurement in intellectual disabilities using true deviation from population norms","volume":"6","author":"Sansone SM","year":"2014","unstructured":"Sansone SM, et al. Improving IQ measurement in intellectual disabilities using true deviation from population norms. J Neurodev Disord. 2014;6(1):16.","journal-title":"J Neurodev Disord"},{"key":"ref15","author":"Sparrow SS","year":"1989","unstructured":"Sparrow SS, Cicchetti DV. The Vineland Adaptive Behavior Scales, in Major psychological assessment instruments, Vol. 2. 1989, Allyn & Bacon: Needham Heights, MA, US. pp. 199\u2013231."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"722378","DOI":"10.3389\/fpsyt.2021.722378","article-title":"Heterogeneity in Fragile X syndrome Highlights the Need for Precision Medicine-Based Treatments","volume":"12","author":"Verdura E","year":"2021","unstructured":"Verdura E, et al. Heterogeneity in Fragile X syndrome Highlights the Need for Precision Medicine-Based Treatments. Front Psychiatry. 2021;12:722378.","journal-title":"Front Psychiatry"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ajmg.a.63027","article-title":"Tissue mosaicism, FMR1 expression and intellectual functioning in males with fragile X syndrome","volume":"191","author":"Baker EK","year":"2023","unstructured":"Baker EK, et al. Tissue mosaicism, FMR1 expression and intellectual functioning in males with fragile X syndrome. Am J Med Genet A. 2023;191(2):357\u201369.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1038\/s41598-022-09633-8","article-title":"Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots","volume":"12","author":"Boggs AE","year":"2022","unstructured":"Boggs AE, et al. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Sci Rep. 2022;12(1):5617.","journal-title":"Sci Rep"},{"issue":"10","key":"ref19","article-title":"FMRP Levels in Human Peripheral Blood Leukocytes Correlates with Intellectual Disability","volume":"11","author":"Roth M","year":"2021","unstructured":"Roth M et al. FMRP Levels in Human Peripheral Blood Leukocytes Correlates with Intellectual Disability. Diagnostics (Basel), 2021. 11(10).","journal-title":"Diagnostics (Basel)"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"115931","DOI":"10.1016\/j.ab.2025.115931","article-title":"Oxford Nanopore third generation sequencing for analysis of FMR1 5'UTR CGG repeat expansions","volume":"706","author":"Yang X","year":"2025","unstructured":"Yang X, et al. Oxford Nanopore third generation sequencing for analysis of FMR1 5'UTR CGG repeat expansions. Anal Biochem. 2025;706:115931.","journal-title":"Anal Biochem"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-11053577\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-11053577\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:20:38Z","timestamp":1790720438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-11053577\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":20,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-11053577\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,9,29]]},"subtype":"preprint"}}